



Substitute for form 1449A/B/PTO

(Use as many sheets as necessary)

Sheet

1

of

1

Application Number

10786,866

Filing Date

February 24, 2004

First Named Inventor

Zhang et al.

Group Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

226236

[illegible][illegible]

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
lv	AF	Acufia et al., "Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Center," <i>J. of Clinical Oncology</i> , 17(1), 74-81 (1999)		
lv	AG	Jahanzeb et al., "Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2* Metastatic Breast Cancer," <i>The Oncologist</i> , 7, 410-417 (2002).		
lv	AH	Sugiyama et al., "Synergistic combined effect of vinorelbine and ZD1839 (Iressa) in NSC cell lines which overexpress the phosphorylated EGFR and ErbB2," <i>KYOWA</i> , 2737.		

Examiner Signature

Kayla

Date Considered

12 | 6 | 0 6

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Unassigned
				Filing Date	February 24, 2004
				First Named Inventor	Zhang et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	226236

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	AA	4,952,408		Rahman	Aug. 28, 1990	
	AB	5,424,073		Rahman et al.	June 13, 1995	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	AC	WO	00/01366	A1	NeoPharm, Inc.	Jan. 13, 2000		
	AD	WO	02/32400	A1	NeoPharm, Inc.	April 25, 2002		

OTHER - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.			Translation	
					Yes	No**
	AE	Waterhouse et al., "A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form: Changing Toxicity Profiles," <i>Drug Safety: An International J. of Med. Toxicology and Drug Experience</i> , Vol. 24(12), 903-920 (2001)				

Examiner Signature	Date Considered	12/6/05
--------------------	-----------------	---------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).